Christoph Lengauer

Blueprint Medicines (United States)

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index77

i10-index128

Publications215

Citations45,059

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last latest available · showing 19 of 19

An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
Science Translational Medicine · 2024-05-29 · 20 citations
Author Correction: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage
Nature · 2023-08-22 · 1 citations
Supplementary Figures 1-4 from PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersPreprint
2023-03-30
Supplementary Figure Legends 1-4 from PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersPreprint
2023-03-30
Supplementary Figures 1-13 from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma CellsPreprint
2023-03-30
Supplementary Methods from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma CellsPreprint
2023-03-30
Supplementary Figure Legends 1-13 from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma CellsPreprint
2023-03-30
Supplementary Table 1 from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells
2023-03-30
Supplementary Figures 1-13 from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma CellsPreprint
2023-03-30
Supplementary Table 1 from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells
2023-03-30
Supplementary Figure Legends 1-13 from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma CellsPreprint
2023-03-30
Supplementary Figure Legends 1-4 from PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersPreprint
2023-03-30
Supplementary Figures 1-4 from PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersPreprint
2023-03-30
Data from PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersPreprint
2023-03-30
Data from PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersPreprint
2023-03-30
Data from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma CellsPreprint
2023-03-30
Supplementary Methods from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma CellsPreprint
2023-03-30
Data from The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma CellsPreprint
2023-03-30
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
Science · 2020-04-28 · 663 citations

Open author page on OpenAlex →